Search
MCMV5322A
go.drugbank.com/drugs/DB17763InvestigationalMCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV3068A] to form RG7667.[A259362]
MCMV3068A
go.drugbank.com/drugs/DB17764InvestigationalMCMV3068A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV5322A] to form RG7667.[A259362]
Iproniazid
go.drugbank.com/drugs/DB04818ApprovedWithdrawnWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Azetukalner
go.drugbank.com/drugs/DB21551InvestigationalAzetukalner is under investigation in clinical trial NCT05718817 (An Open-label Study of XEN1101 in Epilepsy). Azetukalner has a monoisotopic molecular weight of 368.23 Da. … The usage of the INN stem '-kalner' in the name indicates that Azetukalner is a opener of calcium-activated (maxi-K) K+-channel.
Saredutant
go.drugbank.com/drugs/DB06660InvestigationalSaredutant (SR 48968) is a neurokinin-2 antagonist drug being developed as an antidepressant and anxiolytic by Sanofi-Aventis.
MLN2704
go.drugbank.com/drugs/DB06513InvestigationalA Phase 1/2 trial (NCT00070837) evaluated the safety, dosage, and pharmacokinetics of MLN2704 in patients with metastatic androgen-independent prostate cancer.
SR 121463
go.drugbank.com/drugs/DB05455InvestigationalIt is a candidate for control of hyponatremia and in the treatment of syndrome of inappropriate secretion of anti-diuretic hormone (SIADH).
Giredestrant
go.drugbank.com/drugs/DB19125InvestigationalGiredestrant is under investigation in clinical trial NCT06065748 (A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With Er-positive
Efinopegdutide
go.drugbank.com/drugs/DB15077InvestigationalEfinopegdutide is under investigation in clinical trial NCT03606057 (A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy
Q-Derp1
go.drugbank.com/drugs/DB05857ExperimentalQ-Derp1 is developed by Cytos Biotechnology as an immunodrug. It is an antigen for the prevention of various major chronic diseases. Derp1 is the dominant allergic protein found in dust mite feces.